Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Thursday.
According to Zacks, “REXAHN PHARMACTICALS is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn’s compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain quality of life through therapy. “
Several other equities research analysts also recently commented on RNN. HC Wainwright restated a “buy” rating and issued a $19.50 target price on shares of Rexahn Pharmaceuticals in a research note on Monday, November 6th. Seaport Global Securities restated a “buy” rating and issued a $13.00 target price on shares of Rexahn Pharmaceuticals in a research note on Friday, October 6th. Finally, ValuEngine upgraded shares of Rexahn Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, November 2nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $13.65.
Shares of Rexahn Pharmaceuticals (RNN) opened at $2.14 on Thursday. Rexahn Pharmaceuticals has a 52 week low of $1.60 and a 52 week high of $7.10. The firm has a market cap of $64.07, a price-to-earnings ratio of -2.30 and a beta of -0.65.
Large investors have recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Rexahn Pharmaceuticals in the 3rd quarter valued at about $119,000. Sabby Management LLC acquired a new position in shares of Rexahn Pharmaceuticals in the 2nd quarter valued at approximately $706,000. Finally, Susquehanna International Group LLP acquired a new position in shares of Rexahn Pharmaceuticals in the 2nd quarter valued at approximately $2,905,000.
WARNING: “Zacks Investment Research Downgrades Rexahn Pharmaceuticals (RNN) to Hold” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/06/zacks-investment-research-downgrades-rexahn-pharmaceuticals-rnn-to-hold.html.
Rexahn Pharmaceuticals Company Profile
Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.
Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.